Critical role for ventral tegmental glutamate in preference for a cocaine-conditioned environment

Neuropsychopharmacology

Volumn 28, Issue 1, 2003, Pages 73-76

  Harris, Glenda C ^a   Aston Jones, Gary ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMPA receptor antagonist; Cocaine; Dopamine; Glutamate; NMDA receptor antagonist; Place conditioning; Ventraltegmentalarea

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; COCAINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL; ARTICLE; ASSOCIATION; COCAINE DEPENDENCE; DRUG ANTAGONISM; DRUG EFFECT; ENVIRONMENT; MALE; METABOLISM; MICROINJECTION; MOTOR ACTIVITY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RAT; SPRAGUE DAWLEY RAT; VENTRAL TEGMENTUM;

2-AMINO-5-PHOSPHONOVALERATE; 6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; CUES; ENVIRONMENT; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; MALE; MICROINJECTIONS; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; VENTRAL TEGMENTAL AREA;

EID: 0037209158     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300011     Document Type: Article

References (27)

1. Cador M, Bjijou Y, Cailhol S, Stinus L (1999).D-Amphetamine-induced behavioral sensitization: implication of a glutamatergic medial prefrontal cortex-ventral tegmental area innervation.Neuroscience94: 705-721.
2. Cervo L, Samanin R (1995). Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition andexpression of cocaine conditioning place preference.Brain Res673: 242-250.
3. Cornish JL, Nakamura M, Kalivas PW (2001). Dopamineindependent locomotion following blockade of N-methyl-D-aspartate receptors in the ventral tegmental area.J PharmacolExpTher298: 226-233.
4. David V, Durkin TP, Cazala P (1998). Rewarding effects elicited by the microinjection of either AMPA or NMDA glutamatergicantagonists into the ventral tegmental area revealed by anintracranial self-administration paradigm in mice.Eur J Neurosci10: 1394-1402.
5. Ehrman RN, Robbins SJ, Childress AR, O’Brien CP (1992). Conditioned responses to cocaine-related stimuli in cocaineabuse patients.Psychopharmacology (Berl)107: 523-529.
6. Fu Y, Matta S, Gao W, Brower V, Sharp B (2000). Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evalua-tion of the role of N-methyl-D-aspartate receptors in the ventraltegmental area.J PharmacolExpTher294: 458-465.
7. Georges F, Aston-Jones G (2002). Activation of ventral tegmental area cells by the bed nucleus of the striaterminalis: a novelexcitatory amino acid input to midbrain dopamine neurons.JNeurosci22: 5173-5187.
8. Hyman SE, Malenka RC (2001). Addiction and the brain: the neurobiology of compulsion and its persistence.Nat RevNeurosci2: 695-703.
9. Kalivas PW, Alesdatter JE (1993). Involvement of NMDA receptor stimulation in the VTA and amygdala in behavioral sensitizationto cocaine.J PharmacolExpTher267: 486-495.
10. Kalivas PW, Duffy P (1995). Dx receptors modulate glutamate transmission in the ventral tegmental area.J Neurosci15: 5379-5388.
11. Karler R, Calder LD, Bedingfield JB (1994). Cocaine behavioral sensitization and the excitatory amino acids.Psychopharmacol-ogy (Berl)115: 305-310.
12. Kim HS, Park WK, Jang CG, Oh S (1996).Inhibition by MK-801 of cocaine-induced sensitization, conditioned place preference, anddopamine-receptor supersensitivity in mice.Brain Res Bull40:201-207.
13. Kretschmer BD (1999). Modulation of the mesolimbic dopamine system by glutamate: Role of NMDA receptors.J Neurochem78:839-848.
14. Overton P, Clark D (1992).Iontophoretically administered drugs acting at theN-methyl-D-aspartate receptor modulate burstfiring in A9 dopamine neurons in the rat.Synapse10: 131-140.
15. Panos JJ, Rademacher DJ, Renner SL, Steinpreis RE (1999). The rewarding properties of NMDA and MK-801 (dizocilpine) asindexed by the conditioned place preference paradigm.Phar-macolBiochemBehav64: 591-595.
16. Parkinson JA, Cardinal RN, Everitt BJ (2000). Limbic cortical-ventral striatal systems underlying appetitive conditioning.Prog Brain Res126: 263-285.
17. Paxinos G, Watson C (1998).The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego.
18. Pennartz CM, McNaughton BL, Mulder AB (2000).The glutamate hypothesis of reinforcement learning.Prog Brain Res126:231-253.
19. Pierce RC, Meil WM, Kalivas PW (1997). The NMDA antagonist, dizocilpine, enhances cocaine reinforcement without influencingmesoaccumbens dopamine transmission.Psychopharmacology(Berl)133: 188-195.
20. Ranaldi R, French E, Roberts DC (1996). Systemic pretreatment with MK-801 (dizocilpine) increases breaking points for self-administration of cocaine on a progressive-ratio schedule in rats.Psychopharmacology (Berl)128: 83-88.
21. Schenk SS, Valadez AA, Worley CMC, McNamara CC (1993).Blockade of the acquisition of cocaine self-administration by theNMDA antagonist MK-801 (dizocilpine).BehavPharmacol4:652-659.
22. Steinpreis RE, Kramer MA, Mix KS, Piwowarczyk MC (1995).The effects of MK801 on place conditioning.Neurosci Res22:427-430.
23. Svensson T, Mathe J, Nomikos G, Schilstrom B (1998). Role of excitatory amino acids in the ventral tegmental area for centralactions of non-competitive NMDA-receptor antagonists andnicotine.Amino Acids14: 51-56.
24. Ungless MA, Whistler JL, Malenka RC, Bonci A (2001). Single cocaine exposurein vivoinduces long-term potentiation indopamine neurons.Nature411: 583-587.
25. Wolf ME (1998). The role of excitatory amino acids in behavioral sensitization to psychostimulants.ProgNeurobiol54: 679-720.
26. Wolf ME, Jeziorski M (1993). Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather thantransiently masks the development of behavioral sensitization.Brain Res613: 291-294.
27. Zhang XF, Hu XT, White FJ, Wolf ME (1997). Increased responsiveness of ventral tegmental area dopamine neurons toglutamate after repeated administration of cocaine or amphetamine is transient and selectively involves AMPA receptors.JPharmacolExpTher281: 699-706.